Physician profile
Matthew I Gerstein
NPI 1467449256
$3,979.56
in general payments reported to CMS, 2019-2025
32 companies · $717 in 2025
The $717 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,461 · 2020: $133 · 2021: $151 · 2022: $156 · 2023: $755 · 2024: $607 · 2025: $717.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,979 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,979.18 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $894.59 | 2019 | |
| Astellas Pharma US INC | $718.34 | 2019-2025 | Xtandi |
| Teleflex LLC | $447.48 | 2021-2025 | Urolift |
| Janssen Biotech, INC. | $308.84 | 2019-2025 | Erleada |
| Sumitomo Pharma America, INC. | $195.26 | 2023-2025 | Gemtesa, Orgovyx |
| Pfizer INC. | $170.72 | 2019-2025 | |
| Abbvie INC. | $114.69 | 2019-2024 | |
| Convatec INC. | $108.52 | 2023-2025 | |
| Neotract INC. | $98.83 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $93.19 | 2019-2025 | |
| Myriad Genetic Laboratories, INC. | $79.49 | 2023 | Prolaris |
| Urogen Pharma, INC. | $79.23 | 2023-2025 | Jelmyto |
| Dentsply Ih Ab | $78.26 | 2023-2024 | Lofric, Lofric |
| Ferring Pharmaceuticals INC. | $70.51 | 2019-2025 | Adstiladrin |
| Axonics, INC. | $53.73 | 2023-2024 | Axonics |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $50.09 | 2022-2023 | Keytruda, Lynparza |
| Rochester Medical Corporation | $40.96 | 2022 | |
| Procept Biorobotics Corporation | $36.24 | 2025 | |
| Amgen INC. | $35.73 | 2019 | |
| Progenics Pharmaceuticals, INC. | $34.24 | 2023 | Pylarify |
| 180 Medical, INC. | $31.17 | 2024 | Gentlecath |
| Endo Pharmaceuticals INC. | $30.68 | 2019 | |
| Coloplast Corp | $29.76 | 2019 | |
| Boston Scientific Corporation | $26.79 | 2024 | Rezum Generator |
| Blue Earth Diagnostics | $26.77 | 2023 | |
| Telix Pharmaceuticals | $23.87 | 2023 | Illuccix |
| Olympus America INC. | $23.75 | 2025 | Itind System |
| Novartis Pharmaceuticals Corporation | $18.28 | 2024 | |
| Alnylam Pharmaceuticals INC. | $17.16 | 2023 | Oxlumo |
| Avadel Specialty Pharmaceuticals, LLC | $15.86 | 2019 | |
| Tolmar Pharmaceuticals, INC. | $14.28 | 2019 | |
| Myovant Sciences INC. | $12.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Gerstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.